Canary Speech Announces Presence Within Microsoft Booth at HIMSS

February 25, 2025 UCBN News, Syndication Comments Off on Canary Speech Announces Presence Within Microsoft Booth at HIMSS

Strategic partnership with Microsoft provides growth opportunity for Canary Speech, which aims to set new industry standards for managing mental health and cognitive conditions PROVO, Utah, Feb. 25, 2025 /PRNewswire/ — Canary Speech, Inc., a leader in AI-driven vocal biomarker…

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks

Related Articles

No Picture
News

Design Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025

April 21, 2025 UCBN News, Syndication Comments Off on Design Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025

CARLSBAD, Calif., April 21, 2025 (GLOBE NEWSWIRE) — Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that it will present an update on the progress […]

News

Canary Speech Enters Consumer Health Market Through First-of-Its-Kind Partnership with JubileeTV to Advance Proactive Caregiving at Home

February 25, 2026 UCBN News, Syndication Comments Off on Canary Speech Enters Consumer Health Market Through First-of-Its-Kind Partnership with JubileeTV to Advance Proactive Caregiving at Home

Together, Canary Speech and JubileeTV bring clinically informed AI speech analysis into at-home caregiving, offering families early insight into emotional, mental, and cognitive wellness trends through natural conversation PROVO, Utah, Feb. 25, 2026 /PRNewswire/ — […]

News

Halia Therapeutics Joins Forces with Southern Star Research Pty Ltd to Advance Clinical Development of Novel LRRK2 Inhibitor, HT-4253 for Neurodegenerative Diseases

September 3, 2024 UCBN News, Syndication Comments Off on Halia Therapeutics Joins Forces with Southern Star Research Pty Ltd to Advance Clinical Development of Novel LRRK2 Inhibitor, HT-4253 for Neurodegenerative Diseases

LEHI, Utah , Sept. 3, 2024 /PRNewswire/ — Halia Therapeutics, Inc. (Halia), a clinical-stage biopharmaceutical company at the forefront of developing innovative treatments for inflammatory and neurodegenerative diseases, today announced a pivotal strategic collaboration with […]